Zafar Azimov supervised the construction of a medical nutrition plant

On April 24, 2026, the owner of CJSC Infaprim, Zafar Azimov, inspected the construction site of a new plant for the production of therapeutic and enteral nutrition in the Moscow suburb of Istra. The implementation of this project will make it possible to completely replace imports in this area, the company said in a press release.

A new production facility is being built in Istra as part of the import substitution program, as well as a comprehensive modernization of the existing laboratory for quality control of incoming ingredients and finished products. Thus, the project provides for the installation of modern technological equipment, which will increase the capacity and expand the range of specialized products of Infaprim.

The new plant will produce products, including for patients with orphan diseases, a category that is particularly in need of domestic specialized nutrition. The project is aimed at strengthening the technological independence of the industry.

"Providing Russia with domestic therapeutic nutrition is not only an economic issue, but also a matter of national responsibility," Zafar Azimov stressed at a meeting with the project team.

The total investment is 4 billion rubles. After reaching its design capacity, the plant will produce an additional 3 million liters of products per year. The launch of the workshop will also create about 50 new jobs. The construction work is scheduled to be completed in September-October 2026.

CJSC Infaprim produces more than 150 products: infant formula, nutrition for pregnant and lactating women, enteral and therapeutic nutrition, including for children with genetic diseases. Infaprim's cooperation with other domestic companies has made it possible to provide the Russian infant formula market with its own raw materials by 90%. Infaprim CJSC is one of the three leading suppliers of baby food to Central Asian countries and exports products to 12 countries.